CD33 and neoplasm: These subpopulations exhibited differential expression of surface tumor antigens, including the CAR target (i.e., CD33), the NKT TCR target (i.e., CD1d), and NKR ligands (i.e., CD112, CD155, and MICA/B) (Fig. 1c–e).